Vandetanib (ZACTIMATM) is a once-daily oral anticancer drug that selectively targets VEGFR-dependent tumor angiogenesis and REarranged during Transfection (RET)- and epidermal growth factor receptor (EGFR)-dependent tumor cell proliferation and survival. The gene discussed is EGFR; the disease is neoplasm.